CAH - Cardinal Health, Inc.
56.24 0.00 (0.00%)
After hours: 4:59PM EST
| Previous Close | 54.75 |
| Open | 54.93 |
| Bid | 56.12 x 1300 |
| Ask | 56.13 x 1000 |
| Day's Range | 54.75 - 56.27 |
| 52 Week Range | 41.03 - 57.15 |
| Volume | 3,190,438 |
| Avg. Volume | 2,790,981 |
| Market Cap | 16.438B |
| Beta (3Y Monthly) | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -13.97 |
| Earnings Date | Feb 5, 2020 - Feb 10, 2020 |
| Forward Dividend & Yield | 1.92 (3.56%) |
| Ex-Dividend Date | 2019-12-31 |
| 1y Target Est | 51.75 |
- Yahoo Finance Video
Teva climbs despite earnings miss
Teva shares are climbing after the pharmaceutical company raised its guidance for the year. Yahoo Finance’s Akiko Fujita and Ines Ferre break down the quarterly earnings results on The Ticker.
- Zacks
Here's Why You Should Hold Cooper Companies (COO) Stock Now
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.
- Thomson Reuters StreetEvents
Edited Transcript of CAH earnings conference call or presentation 7-Nov-19 1:00pm GMT
Q1 2020 Cardinal Health Inc Earnings Call
- InvestorPlace
8 Dividend Aristocrat Stocks to Buy Now
Even though the U.S.-China trade war is seemingly easing, it could flare back up again at any time. As a result, many investors are still looking for defensive stocks to buy now. Of course, in the most extreme example, you can elect to go all into cash. However, history has proven that to be the worst thing to do. Instead, this is a good time to consider dividend aristocrats.First, market uncertainty incentivizes stable dividend stocks to buy now. How so? Passive-income generating companies typically perform better than high-flying growth names during bearish phases. For one thing, investors can still collect their payouts even if their portfolio isn't doing too well. Moreover, organizations that have a history of consistent payouts tend to be levered toward secular or otherwise steady industries.And there's no better paragon of stability than dividend aristocrats. For those who are unfamiliar with the term, dividend aristocrats have three main requirements: they must be equities traded in the S&P 500, have 25 years-plus of dividend increases and meet size/liquidity benchmarks.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Large-Cap Stocks to Give a Wide Berth However, a word of caution. Just because you put dividend aristocrats in your list of stocks to buy now doesn't guarantee a smooth ride. If the markets turn volatile, you can expect virtually all names to incur red ink.But the major selling point is magnitude. With dividend aristocrats, you're limiting your potential losses due to the robustness of the target company. Better yet, the volatility provides a rare discount for these stalwarts of industry.So with that in mind, here are eight stocks to buy now with a long track record of payouts: Stocks to Buy: McDonald's (MCD)Source: Shutterstock Dividend Yield: 2.6%I'm going to start my list of stocks to buy now with a name I was wrong about: McDonald's (NYSE:MCD). One of the reasons why I didn't like MCD stock was that the Golden Arches apparently wasn't winning over millennials. But recently, I started eating out at McDonald's, and I discovered that the real fundamentals don't match the "paper" data.For instance, the McDonald's app is incredibly convenient. You order what you want on your phone and go up to the counter or the drive-thru. Very quickly, their employees deliver your selected items. And let's talk about the drive-thru: it's lightning-quick, even with rows of waiting cars. That's a major plus for MCD stock.Finally, McDonald's is a proud member of the dividend aristocrats. It has increased its payout consistently over a 43-year period. If a downturn were to impact the markets, MCD stock is a name you'll want to own. Colgate-Palmolive (CL)Source: Shutterstock Dividend Yield: 2.6%When you're on the hunt for stable stocks to buy now, you don't want to get too cute. Instead, you'll want to go with a proven name like Colgate-Palmolive (NYSE:CL). The investment thesis for CL stock is straightforward and simple. Even in times of recession, people still need to brush their teeth. Thus, I expect a steady revenue stream no matter what happens in the coming months and years. * 7 Large-Cap Stocks to Give a Wide Berth I believe CL stock will give you excellent protection over the coming months. Keep in mind that Colgate-Palmolive has increased their dividends for 55 years. That's an impressive feat, even compared to other dividend aristocrats. Further, it's a status that management won't give up without a fight. Cardinal Health (CAH)Source: Shutterstock Dividend Yield: 3.6%In recent years, the healthcare sector has suffered a black eye from a public relations standpoint. Thus, it's no surprise that many companies in this segment have faltered. However, I'd consider putting Cardinal Health (NYSE:CAH) on your list of stocks to buy now. Unlike other players in this broad category, CAH stock is strongly levered to secular demand.In other words, Cardinal Health has a wide range of professional medical products. They run the gamut from anesthesia-related equipment to laboratory products down to something as mundane as gloves. While medical technology is always improving, some things will always remain the same. For these everyday concerns in the medical field, Cardinal Health has folks covered. Ultimately, that's a great catalyst for CAH stock.Another factor is that the company very much belongs on the list of dividend aristocrats. While the exact number of dividend increases causes some disagreement, CAH is included in the Proshares S&P 500 Dividend Aristocrats ETF (BATS:NOBL). And whatever the case, it has reliably raised dividends for at least the last 14 years. Aflac (AFL)Source: Shutterstock Dividend Yield: 2%Simply put, Aflac (NYSE:AFL) is a great company with an incredibly relevant service. As you no doubt have learned through their quirky commercials, Aflac specializes in supplemental insurance. Essentially, their range of products protect you financially from incidents that "regular" insurance doesn't cover or cover adequately. Plus, their solutions represent an incremental cost for much peace of mind, bolstering the case for AFL stock.And while most millennials probably think they're invincible, many will encounter situations that give them a reality check. Additionally, they may hear horror stories about how coverage gaps financially ruined one of their peers. Whatever the case, Aflac, and by logical deduction, AFL stock, has opportunities to rise through word of mouth. * 7 Large-Cap Stocks to Give a Wide Berth Finally, Aflac is one of the most stable stocks to buy now among dividend aristocrats. Kimberly-Clark (KMB)Source: Shutterstock Dividend Yield: 3.1%I don't always prepare for recessions. But when I do, I take a long look at Kimberly-Clark (NYSE:KMB). If you're concerned about a prolonged downturn in the U.S. or global economy, you'll also want to consider KMB stock. As with Colgate-Palmolive, the bullish argument here is very simple: even in recessions, people need to use the bathroom.And without getting graphic, people also need to take care of themselves after a lengthy session with the porcelain throne. Kimberly-Clark offers some of the best products for this endeavor, and I speak from personal experience. Moreover, the company has other family-care products. If you think about it, KMB stock is truly a cradle-to-grave investment.Kimberly-Clark has traded among dividend aristocrats for 46 years. That makes its shares one of the stocks to buy now in my book. Chevron (CVX)Source: Shutterstock Dividend Yield: 3.9%With the U.S. and China trading barbs and sanctions, it's no surprise that oil companies like Chevron (NYSE:CVX) fell. On surface level, CVX stock currently faces two major headwinds. First, global volatility means lower demand overall for energy. Second, the push for clean and renewable energies makes CVX stock appear antiquated, and perhaps soon approaching irrelevancy.Admittedly, the first point is going to be a major distraction for Chevron. However, even in the middle of a recession, people still require transportation. Thus, I don't see demand falling completely off the cliff. On the second point, I believe green energy is more a gimmick than a practical reality. Our infrastructure is simply not ready to accommodate innovations like electric vehicles on a mass scale. * 7 Large-Cap Stocks to Give a Wide Berth Granted, CVX stock is a risky play among this list of stocks to buy now. That said, the trade war dynamic should drive shares to an attractive discount. At that point, I think Chevron becomes a bargain because the world still needs fossil-fuel-based energy. AT&T (T)Source: Shutterstock Dividend Yield: 5.2%With AT&T (NYSE:T), we're really getting into the riskier side of the dividend stocks to buy now. I say this for a couple of reasons. One, with a yield of 5.2%, sustainability becomes a concern. Second, and a perfect segue, the dividend payout ratio for T stock is on-paper astronomical. Therefore, many bears anticipate that AT&T will lose its status as one of the key dividend aristocrats.However, it's important to point out that telecoms usually have extremely large depreciation and amortization costs. That artificially depresses earnings, which makes the high payout ratio somewhat deceptive. Still, I concede the point that T stock is saddled with an unprecedented debt level. Its big-moat, slow-growth narrative is distracting, especially when we may be headed toward a recession.That said, this criticism focuses on the headline print. In reality, AT&T is one of very few companies that have the resources and know-how to roll out the 5G network. And because we're in a tech cold war with international adversaries, I see the government supporting T stock big time. 3M (MMM)Source: Shutterstock Dividend Yield: 3.4%Last on my list of stocks to buy now is applied-sciences firm 3M (NYSE:MMM). After providing largely steady gains over the last several decades, MMM stock is in trouble. Hitting a peak around February of 2018, shares have formed an ugly bearish trend channel. Efforts to time the bottom have badly bruised speculators.Surely, I'm not alone when I say that I dislike the phrase "this time, it's different." It's almost bad karma to use those words when discussing an investment thesis. However, I genuinely believe that with MMM stock, this is a valid descriptor.One of the toughest challenges for MMM stock is that the underlying company didn't have a relevant product. That calculus has changed with their latest "Flex & Seal Shipping Roll." Essentially, this is a customizable shipping package that doesn't require tape or other cumbersome equipment.Looking at the video demonstration of Flex & Seal, I think it's a game-changer for retail. By logical deduction, then, it's a game-changer for MMM stock.As of this writing, Josh Enomoto is long T stock. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Large-Cap Stocks to Give a Wide Berth * 7 Potential New Stocks That Should Not Go Public * 5 Chinese Stocks to Buy Surging Higher The post 8 Dividend Aristocrat Stocks to Buy Now appeared first on InvestorPlace.
- American City Business Journals
Cardinal Health agrees to pay $5.63B to settle claims in opioid crisis
Cardinal Health Inc.'s share of a preliminary $47 billion settlement for about 2,700 opioid lawsuits from states and municipal governments is $5.63 billion, the Dublin company said in announcing first-quarter results.
- Simply Wall St.
Is Cardinal Health, Inc. (NYSE:CAH) Trading At A 23% Discount?
Today we will run through one way of estimating the intrinsic value of Cardinal Health, Inc. (NYSE:CAH) by taking the...
- Barrons.com
Teva’s CEO Says Opioid Deal Could Be Done By End of the Year
As shares of (TEVA) soared 10% after the company reported solid earnings on Thursday, CEO Kåre Schultz said the litigation the company faces over its alleged role in the opioid crisis could be resolved by the end of this year. “I think that’s a realistic timeline,” Schultz said in an interview with Barron’s. If that happens, it would lift a weight that has helped drive Teva (ticker: TEVA) shares down 81% between the end of October in 2016 and the end of October this year.
- Barrons.com
Teva and Other Opioid Defendant Stocks Jump on Strong Earnings
The sprawling litigation seeking to extract billions from corporations over the opioid crisis is far from over, but investors could be forgiven for thinking it was on Thursday morning.
- Zacks
Cardinal Health (CAH) Q1 Earnings & Revenues Beat Estimates
Cardinal Health (CAH) Q1 results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
- Zacks
Cardinal Health (CAH) Q1 Earnings and Revenues Top Estimates
Cardinal (CAH) delivered earnings and revenue surprises of 16.51% and 0.99%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- MarketWatch
Cardinal Health reports $4.9 billion loss due to opioid agreements
Cardinal Health reported a $4.92 billion loss, or $16.65 a share, in the fiscal first quarter, due to an agreement in principle it reached in October to pay $5.56 billion to settle pending and potential opioid lawsuits. The company had earnings of $593 million, or $1.94 a share, for the like period a year ago. Excluding one-time charges, adjusted EPS was $1.27, above the FactSet consensus of $1.10. Revenue rose 6% to $37.34 billion, beating the FactSet consensus of $36.73 billion. Cardinal reaffirmed its 2020 adjusted EPS guidance of $4.85 to $5.10. As part of the recent opioid action, the company also last month settled with two Ohio counties for $66 million. Cardinal's stock has gone up 15.3% year-to-date, while the S&P 500 has risen about 23%.
- PR Newswire
Cardinal Health Reports First Quarter Results for Fiscal Year 2020
- Revenue increased 6 percent to $37.3 billion - GAAP(1) operating loss was $5.3 billion and included a $5.6 billion accrual related to opioid litigation, non-GAAP operating earnings increased 6 percent ...
- Zacks
Medical Products' Nov 7 Earnings Roster: ABC, CAH & More
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
- Zacks
Why Earnings Season Could Be Great for Cardinal Health (CAH)
Cardinal Health (CAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Zacks
Can Pharmacy Services Drive CVS Health's (CVS) Q3 Earnings?
CVS Health's (CVS) Caremark legacy business is expected to have delivered a solid third quarter, backed by the company's robust execution of its formulary and cost-containment tools.
- Zacks
What's in the Cards for Cardinal Health (CAH) in Q1 Earnings?
Cardinal Health (CAH) Q1 earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.
- Zacks
What's in the Cards for DaVita (DVA) This Earnings Season?
DaVita (DVA) expects to have gained from calcimimetics in the third quarter.
- Zacks
Can All-Line Growth Boost CVS Health's (CVS) Q3 Earnings?
The newly-incorporated Health Care Benefits business already registers top-line contributions for CVS Health (CVS).
- American City Business Journals
Scorecard: A year ago, NaviHealth was bought by a private equity firm. Here's what's happened since
Scorecard: A year ago, NaviHealth was bought by a private equity firm. Here's what's happened since
- Zacks
Cardinal Health (CAH) Expected to Beat Earnings Estimates: Should You Buy?
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Will Genetic Testing Drive Invitae's (NVTA) Q3 Earnings?
Several bio-pharma partnerships and acquisitions are likely to have contributed to Invitae's (NVTA) top line in Q3.
- Zacks
Can Dental Growth Drive Henry Schein's (HSIC) Q3 Earnings?
The robust performance of the Primescan system in Europe and the United States is expected to have contributed to Henry Schein's (HSIC) top line during Q3.
- Zacks
Can BD Medical Drive Becton, Dickinson's (BDX) Q4 Earnings?
Headwinds in the DCB business and unfavorable foreign exchange rates might have partially impacted Becton, Dickinson's (BDX) fiscal Q4 performance.
